Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G S Tillotson

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Chest|August 12, 2000
Implementation and physician behavior change : an industry perspectiveG S Tillotson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2001
Derriere to the future: is it time to rethink how we use antimicrobial agents?G S Tillotson
The Annals of Pharmacotherapy|January 17, 2002
Comment: peripheral neuropathy syndrome and fluoroquinolonesG S Tillotson
Journal of Clinical Pathology|April 1, 1982
An evaluation of the API-20 STREP systemG S Tillotson
Journal of Medical Microbiology|May 1, 1996
Quinolones: structure-activity relationships and future predictionsG S Tillotson
Journal of Clinical Pathology|August 1, 1981
Evaluation of ten commercial blood culture systems to isolate a pyridoxal-dependent streptococcusG S Tillotson
Pharmacotherapy|March 20, 2001
New milestones achieved in fluoroquinolone safetyG S Tillotson, J Rybak
Chest|December 24, 1997
Antibiotic selection and dosing for the treatment of acute exacerbations of COPDJ J Schentag, G S Tillotson
Chest|July 14, 2001
Fluoroquinolone pharmacodynamics and efficacyG V Doern, G S Tillotson
International Journal of Antimicrobial Agents|July 27, 1999
Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infectionsJ M Blondeau, G S Tillotson
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Chest|August 12, 2000
Implementation and physician behavior change : an industry perspectiveG S Tillotson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2001
Derriere to the future: is it time to rethink how we use antimicrobial agents?G S Tillotson
The Annals of Pharmacotherapy|January 17, 2002
Comment: peripheral neuropathy syndrome and fluoroquinolonesG S Tillotson
Journal of Clinical Pathology|April 1, 1982
An evaluation of the API-20 STREP systemG S Tillotson
Journal of Medical Microbiology|May 1, 1996
Quinolones: structure-activity relationships and future predictionsG S Tillotson
Journal of Clinical Pathology|August 1, 1981
Evaluation of ten commercial blood culture systems to isolate a pyridoxal-dependent streptococcusG S Tillotson
Pharmacotherapy|March 20, 2001
New milestones achieved in fluoroquinolone safetyG S Tillotson, J Rybak
Chest|December 24, 1997
Antibiotic selection and dosing for the treatment of acute exacerbations of COPDJ J Schentag, G S Tillotson
Chest|July 14, 2001
Fluoroquinolone pharmacodynamics and efficacyG V Doern, G S Tillotson
International Journal of Antimicrobial Agents|July 27, 1999
Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infectionsJ M Blondeau, G S Tillotson
Pageof 6